Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice

Disclosures: This project was funded by CSL Limited. SJB and GV are employees of CSL Limited. RBL received and AFL receives funding from CSL Limited. All other authors have no relevant conflicts of interest to declare.

Contributions: EML and DY planned and performed the experiments, and wrote the manuscript. SJB and GV were responsible for the production and design of CSL362, and planned the experiments, and provided editorial and scientific advice for this manuscript. AW, JFM and NC planned and conducted the mutational analyses of the AML xenografts and provided editorial and scientific advice for this manuscript. MNM optimized the AraC/DNR combination protocol. HSR, JAP, AFL, IDL prepared the patient samples for the establishment of AML xenografts, and related consultations. RBL planned the experiments and wrote the manuscript.